top of page
  • Writer's pictureSBIJI Innovation

Biond Biologics Announces Poster Presentations at AACR 2020 Virtual AnnualMeeting

July 9, 2020

Published work highlights the preclinical development of BND-22, an anti-ILT2 multi-cell checkpoint inhibitor that enhances the anti-tumor activity of innate and adaptive immune cells Also, first publication of a regulatory mechanism of the CD28/B7 immune stimulatory pathway, identifying CD28 shedding as a potential novel target for cancer therapeutics

14 views0 comments

Recent Posts

See All


bottom of page